Sanofi and Regeneron's Dupixent Shows Promising Results in Second COPD Trial

The companies plan to seek FDA approval by the end of the year, potentially expanding the use of the drug currently used for eczema and asthma.

Sanofi and Regeneron's anti-inflammatory drug Dupixent has shown significant benefits in a second large trial for treating chronic obstructive pulmonary disease (COPD), also known as 'smoker's lung'.
The second phase 3 trial showed that Dupixent reduced exacerbations of the disease by 34%, confirming positive results from a first trial known as BOREAS earlier this year.
The companies plan to file a request for approval with the Food and Drug Administration (FDA) by the end of the year.
Using Dupixent for COPD could add billions to Sanofi's growth prospects, but would also increase its heavy reliance on the drug, which is currently used to treat eczema, asthma, and other inflammatory conditions.
Details of the second trial will be presented at an as yet undisclosed medical conference.